Data presented at Hawaiian Eye and Retina 2025 Meeting Results confirmed that intravitreal ONS-5010 provided early and sustained anatomic improvements, with steady gains in BCVA and reliable, consistent safety ONS-5010 demonstrated to be non-inferior to Lucentis at 4 and 12 weeks Company on track

Live webcast on Wednesday, January 29th at 2:00 PM ET ISELIN, N.J. , Jan. 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom ( UK ) earlier this year for the first

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeks BLA resubmission on track for calendar Q1 2025 Entered into agreements for warrant inducement transaction expected to result in up to $20.4 million in gross proceeds ISELIN, N.J. , Jan. 16, 2025 (GLOBE NEWSWIRE) -- Outlook

Jedd Comiskey , Senior Vice President, Head of Europe , highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J. , Jan. 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom ( UK ); First commercial launch anticipated in H1 CY25 Received NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD

Full NORSE EIGHT Data Readout Expected January 2025 ISELIN, N.J. , Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom ( UK ) 40,000 new wet AMD patients each year

ISELIN, N.J. , Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab

Final efficacy data expected in January 2025 Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J. , Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom

Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET ISELIN, N.J. , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the